Purpose We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients
with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, …

Background Most data on intensive care unit (ICU) patients with COVID‐19 originate in
selected populations from stressed healthcare systems with shorter term follow‐up. We present …

Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given
daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe …

Background The coronavirus disease 2019 (COVID‐19) pandemic has resulted in millions
of deaths and overburdened healthcare systems worldwide. Systemic low‐dose …

Background Characteristics and care of intensive care unit (ICU) patients with COVID‐19
may have changed during the pandemic, but longitudinal data assessing this are limited. We …

Background Among ICU patients with COVID‐19, it is largely unknown how the overall
outcome and resource use have changed with time, different genetic variants, and vaccination …

Background Coronavirus disease 2019 (COVID‐19) can lead to severe hypoxic respiratory
failure and death. Corticosteroids decrease mortality in severely or critically ill patients with …

Objective To identify PaCO 2 trajectories and assess their associations with mortality in critically
ill patients with coronavirus disease 2019 (COVID‐19) during the first and second waves …

IMPORTANCE Dexamethasone 6 mg daily is recommended for up to 10 days in patients
with severe and critical COVID-19, but a higher dose may benefit those with more severe …

Background In the COVID-STEROID 2 trial there was suggestion of heterogeneity of treatment
effects (HTE) between patients enrolled from Europe vs. India on the primary outcome. …